MAP3K5 and Hepatic fibrosis: Nevertheless, a recent phase 2b trial showed that the combination of selonsertib with firsocostat or cilofexor for 48 weeks did not result in fibrosis regression at the levels of liver histology, imaging, and noninvasive markers (Loomba et al., 2021b), indicating that the anti-liver fibrosis effect of ASK1 inhibitors are not obvious in clinical practice.